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JIntroduction: Chemotherapy for breast cancer has been associated with cognitive problems;
however, the impact of adjuvant hormone therapy is less clear. No studies have explored provider
discussions about cognitive concerns or factors associated with neurocognitive treatment. This study
examined cognitive problems, factors associated with having a provider discussion, and receipt of
neurocognitive treatment.
Methods: Female breast cancer survivors (N¼2,537) from the Sister Study and the Two Sister
Study who were at least 1 year post-treatment were surveyed in 2012 about their cancer therapies
(conﬁrmed by medical records); cognitive concerns; related provider discussions; and neuro-
cognitive treatment. A total of 2,296 women were included in the current 2014 analysis. Extensive
covariate information was also ascertained for predictive multivariate models.
Results: The prevalence of self-reported cognitive problems after treatment was 60%. Of those
reporting cognitive problems, only 37% had discussed those concerns with a provider and 15% had
been treated for cognitive symptoms. The odds of reported cognitive concerns that started during and
after treatment were elevated for those who received only hormone therapy and no chemotherapy
(OR¼1.64, 95% CI¼1.15, 2.33); chemotherapy and no hormone therapy (OR¼5.63, 95% CI¼3.52,
9.00); or both (OR¼6.33, 95% CI¼4.21, 9.54) compared with those reporting neither treatment.
Conclusions: The high prevalence of cognitive concerns underscores the importance of monitoring
breast cancer survivors for potential neurocognitive effects of hormone and chemotherapy,
discussions with survivors about those concerns, and treatment referrals. Monitoring changes over
time can help to evaluate both psychosocial and neurocognitive care provided for survivors.
(Am J Prev Med 2015;49(6S5):S498–S508) Published by Elsevier Inc. on behalf of American Journal of
Preventive Medicine. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).IntroductionAlthough advances in chemotherapy and otheradjuvant treatments have contributed toimproved outcomes for women diagnosed with
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This is an open access article under the CC BY-NCbreast cancer, these therapies can have persistent side
effects.1 Cross-sectional studies2,3 have found that 17%–
75% of breast cancer survivors subjectively experience
cognitive impairment after chemotherapy. Cognitive
impairments, including problems with learning, lan-
guage, and concentration, can profoundly affect a survi-
vor’s daily functioning.
A large proportion of patients treated with chemo-
therapy (CTX) also receive hormonal adjuvant therapies
(HTX) such as the estrogen receptor antagonist tamox-
ifen or aromatase inhibitors. Research ﬁndings examin-
ing the inﬂuence of CTX and HTX on reported
neurocognitive functioning among breast cancer survi-
vors are varied, and there is little research examining
cognitive effects of HTX use among premenopausalsevier Inc. on behalf of American Journal of Preventive Medicine.
-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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survivors (compared with healthy controls) found use of
HTX (e.g., tamoxifen and exemestane) to be associated
with lower cognitive functioning (e.g., verbal memory,
executive functioning),4–6 whereas other studies have
reported no association.7 The strengths of these
associations have also varied based on the type of HTX
used.8
Patient and provider discussions regarding treatment-
induced cognitive concerns are underexplored, and
studies often do not distinguish discussions speciﬁc to
neurocognitive dysfunction from those related to emo-
tional/behavioral concerns. One recent estimate is that
31% of cancer survivors had a provider discussion about
psychosocial concerns,9 but it is unclear if these dis-
cussions included neurocognitive symptoms.
There is also limited information on receipt of neuro-
cognitive treatments and interventions (e.g., neurocog-
nitive testing, behavioral therapy, psychostimulants, and
alternative treatments). Only 14% of survivors partici-
pated in counseling in one population-based study.10
Though breast cancer survivors and survivors diagnosed
fewer than 5 years previously are more likely to receive
counseling and supportive services (compared with
survivors with other cancers and survivors diagnosed
more than 5 years previously),9,11 it is unclear if these
services are used to decrease cognitive effects related to
cancer treatment.
The current study explored characteristics of survi-
vors by treatment type, predictors of self-reported
cognitive impairment, patient–provider discussions,
and receipt of neurocognitive treatment. Although
some relationships explored were descriptive and
hypothesis generating, the authors predicted that
receipt of CTX, HTX, or both (compared with no
treatment) would be associated with cognitive impair-
ment and that daily living concerns would be associated
with having provider discussions and receipt of neuro-
cognitive treatment.Methods
In 2012, CDC and the National Institute of Environmental Health
Sciences carried out the CDC Sisters Study Survivorship Survey
(Survivorship Survey), to examine survivorship concerns among
women with a prior diagnosis of breast cancer. The Survivorship
Survey included women diagnosed with breast cancer who were
enrolled in either the Sister Study, a cohort of initially breast cancer–
free women whose sister had been diagnosed with breast cancer, or
the Two Sister Study, an ancillary study of women with young-onset
(diagnosed age o50 years) breast cancer who had a sister in the
Sister Study cohort. Study design and methodology for the Sister
Study and the Two Sister Study are described on the study website
(www.sisterstudy.org) and in previous publications.12–14December 2015The 2,832 women eligible for the Survivorship Survey were
aged 34–82 years, lived in the U.S. or Puerto Rico, spoke English,
and met all other Sister or Two Sister Study inclusion criteria
(www.sisterstudy.org). Sister Study participants were eligible if
their ﬁrst breast cancer (ductal carcinoma in situ or invasive
breast cancer) was diagnosed by October 9, 2012, and they
completed study follow-up activities. All Two Sister Study
participants were eligible for the Survivorship Survey. Invited
participants were offered a $20 Visa gift card. The survey took no
more than 1.5 hours to complete and was approved by relevant
IRBs (OMB Control 0925-0522). A total of 2,537 women
completed the Survivorship Survey via mailed, paper question-
naire (n=2,378) or computer-assisted telephone interview
(n=159), for a response rate of 90.3%. After implementing
exclusion criteria for the study, 2,296 women were included in
the analytic sample, and 241 were excluded.
Measures
The Survivorship Survey included questions on medical history,
health behaviors, employment, quality of life, and other aspects of
the survivor experience. Survey questions used in the current
analysis were taken from existing surveys,15–19 were newly
developed, or modiﬁed based on existing validated measures
(Appendix, available online).
Years since diagnosis, age at diagnosis, breast cancer type,
race/ethnicity, marital status, education, U.S. region of resi-
dence, and employment were recoded as categorical variables
(Table 1).
Survey and medical records data were combined to categorize
participant’s treatment for ﬁrst breast cancer (source agreement
was 490%). Using an algorithm (Figure 1), respondents were
classiﬁed into four mutually exclusive treatment groups: CTX
alone, HTX alone, CTX and HTX, and neither CTX nor HTX.
Respondents were excluded if they had Stage 4 cancer and
radiation, or Stage 3 cancer and reported their breast cancer had
metastasized (n¼59) because of the possibility of radiation to the
central nervous system and associated neurocognitive deﬁcits.
Problems with thinking, memory, and attention and trouble with
concentration, short-term memory, recall memory, organizing daily
functions, and multitasking were assessed (Appendix, available
online). Respondents who experienced symptoms sometimes,
often, or always were categorized as having “neurocognitive
concerns.” Additional questions asked included when respondents
ﬁrst noticed neurocognitive symptoms, if they experienced any
improvement, and if they spoke to their doctor (yes or no) or
received treatments for neurocognitive symptoms. A variable for
daily living concerns was created based on how many daily living
tasks the respondent’s neurocognitive symptoms interfered with,
categorized as zero to one, two to three, four to ﬁve, or six to eight
(Appendix, available online).
Statistical Analysis
Statistical analyses were performed in 2014 with SAS, version 9.3.
Descriptive statistics for study variables were reported separately
by cancer treatment group (Table 1).
Multivariable logistic regression models were used to assess
factors associated with three outcomes: reported neurocognitive
concerns (Table 2); provider discussions; and treatment receipt for
Table 1. Characteristics of Breast Cancer Survivors by Adjuvant Treatment Type, Sister Study Survivorship Survey, 2014
Characteristics
CTX not HTX,
n (%)
HTX not CTX,
n (%)
Both CTX and HTX,
n (%)
Neither CTX or HTX,
n (%)
Total (all BCS) 288 (100) 822 (100) 859 (100) 327 (100)
Years since diagnosis
o5 99 (34.38) 510 (62.12) 246 (28.64) 179 (54.74)
Z5 189 (65.63) 311 (37.88) 613 (71.36) 148 (45.26)
Age at diagnosis (years)
28–39 32 (12.65) 5 (0.69) 57 (7.61) 11 (3.81)
40–49 133 (52.57) 209 (28.99) 486 (64.89) 93 (32.18)
50–59 37 (14.62) 140 (19.42) 110 (14.69) 85 (29.41)
60–69 41 (16.21) 244 (33.84) 71 (9.48) 69 (23.88)
70–78 10 (3.95) 123 (17.06) 25 (3.34) 31 (10.73)
Age at survey (years)
34–44 20 (7.91) 8 (1.08) 45 (5.94) 7 (2.48)
45–54 122 (48.22) 194 (26.22) 421 (55.54) 82 (29.08)
55–64 69 (27.27) 205 (27.70) 198 (26.12) 101 (35.82)
65–74 34 (13.44) 242 (32.70) 74 (9.76) 71 (25.18)
75–82 8 (3.16) 91 (12.30) 20 (2.64) 21 (7.45)
Breast cancer type
In situ 2 (0.69) 227 (27.62) 8 (0.93) 228 (69.72)
Invasive 285 (98.96) 593 (72.14) 851 (99.07) 97 (29.66)
Menopausal status
Postmenopausal 122 (42.66) 548 (67.49) 266 (31.07) 191 (59.13)
Premenopausala throughout tx 86 (30.07) 156 (19.21) 230 (26.87) 104 (32.20)
Treatment-induced menopause 78 (27.27) 108 (13.30) 360 (42.06) —b
Race
White, non-Hispanic 240 (83.33) 745 (90.63) 786 (91.50) 291 (89.54)
Black, non-Hispanic 34 (11.81) 32 (3.89) 27 (3.14) 15 (4.62)
Other 14 (4.86) 45 (5.47) 46 (5.36) 19 (5.85)
Marital status
Single/never married 17 (5.90) 51 (6.20) 48 (5.59) 18 (5.54)
Married/committed relationship 216 (75.00) 634 (77.13) 712 (82.89) 251 (77.23)
Divorced/widowed/separated 55 (19.10) 137 (16.67) 99 (11.53) 56 (17.23)
Education
High school or less 44 (15.28) 116 (14.11) 101 (11.76) 35 (10.77)
Some/associate/technical degree 81 (28.13) 243 (29.56) 244 (28.41) 79 (24.31)
Four-year degree 90 (31.25) 240 (29.20) 287 (33.41) 113 (34.77)
Master’s and above 73 (25.35) 223 (27.13) 227 (26.43) 98 (30.15)
(continued on next page)
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Table 1. Characteristics of Breast Cancer Survivors by Adjuvant Treatment Type, Sister Study Survivorship Survey, 2014
(continued)
Characteristics
CTX not HTX,
n (%)
HTX not CTX,
n (%)
Both CTX and HTX,
n (%)
Neither CTX or HTX,
n (%)
Region of country
Northeast 42 (14.63) 156 (19.00) 134 (15.62) 65 (19.94)
Midwest 99 (34.49) 237 (28.87) 279 (32.52) 79 (24.23)
South 91 (31.71) 235 (28.62) 243 (28.32) 93 (28.53)
West 55 (19.16) 193 (23.51) 202 (23.54) 89 (27.30)
Employment
Employed for wages 195 (68.42) 428 (52.32) 617 (72.16) 181 (55.35)
Out of work/unable to work 36 (12.63) 61 (7.46) 109 (12.75) 45 (13.76)
Retired 47 (16.49) 314 (38.39) 109 (12.75) 94 (28.75)
Reported neurocognitive concerns (thinking, memory, and/or attention)
Any concerns (a little/quite a bit/very much) 213 (73.96) 371 (45.30) 672 (78.23) 125 (38.46)
Very much 30 (10.42) 12 (1.47) 63 (7.33) 2 (0.62)
Quite a bit 48 (16.67) 64 (7.81) 175 (20.37) 17 (5.23)
A little 135 (46.88) 295 (36.02) 434 (50.52) 106 (32.62)
None 75 (26.04) 448 (54.70) 187 (21.77) 200 (61.54)
Speciﬁc neurocognitive concerns
Concentration/focus troublec
Yes 147 (69.67) 256 (71.11) 455 (68.11) 91 (73.39)
No 64 (30.33) 104 (28.89) 213 (31.89) 33 (26.61)
Short-term memory troublec
Yes 167 (79.15) 284 (77.81) 500 (74.63) 93 (75.61)
No 44 (20.85) 81 (22.19) 170 (25.37) 30 (24.39)
Recall memory troublec
Yes 159 (75.71) 277 (75.68) 511 (76.38) 94 (75.81)
No 51 (24.29) 89 (24.32) 158 (23.62) 30 (24.19)
Trouble with organizingc
Yes 77 (37.02) 131 (36.59) 245 (36.84) 45 (36.89)
No 131 (62.98) 227 (63.41) 420 (63.16) 77 (63.11)
Trouble with multitaskingc
Yes 98 (46.67) 155 (43.06) 311 (46.91) 64 (52.46)
No 112 (53.33) 205 (56.94) 352 (53.09) 58 (47.54)
First noticed cognitive concernsc
Before diagnosed with breast cancer 9 (4.35) 93 (26.42) 44 (6.64) 41 (34.75)
During and/or o6 months after
treatment
159 (76.81) 138 (39.20) 488 (73.60) 32 (27.12)
More than 6 months after treatment 39 (18.84) 121 (34.38) 131 (19.76) 45 (38.14)
(continued on next page)
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Table 1. Characteristics of Breast Cancer Survivors by Adjuvant Treatment Type, Sister Study Survivorship Survey, 2014
(continued)
Characteristics
CTX not HTX,
n (%)
HTX not CTX,
n (%)
Both CTX and HTX,
n (%)
Neither CTX or HTX,
n (%)
Improvements in cognitionc
Improved a lot/little 66 (31.43) 65 (17.86) 190 (28.40) 21 (16.80)
Stayed the same / got worse 144 (68.57) 299 (82.14) 479 (71.60) 104 (83.20)
aPremenopausal refers to women who were premenopausal prior to and remained premenopausal after treatment.
bData were suppressed for women who did not receive either CTX or HTX and reported experiencing treatment-induced menopause (n¼28).
cThese questions were only asked of individuals who reported having any neurocognitive concerns.
BCS, breast cancer survivors; CTX, chemotherapy; HTX, hormonal therapy for breast cancer; tx, treatment.
Buchanan et al / Am J Prev Med 2015;49(6S5):S498–S508S502neurocognitive symptoms (Table 3). Unadjusted bivariate analyses
were ﬁrst conducted to examine the association between scientiﬁ-
cally relevant individual characteristics and the three outcomes.
Correlation coefﬁcients and chi-square statistics were used to
assess the association between variables. Final adjusted models to
determine predictors of each outcome included all potential
predictors that had been examined in unadjusted bivariate analyses
as well as age at survey, which was assessed in 10-year categories
using dummy variables. Women who reported that they had been
premenopausal and aged Z60 years at diagnosis were excludedDid you receive the total num
that your doctor believed we
Did your doctor prescribe hormonal therapies (HTX), 
like tamoxifen (also called Nolvadex), Arimidex 
(anastrozole), Aromasin (exemestane), or Femara 
(letrozole) for your breast cancer?
Yes
Yes
No
Medical record (MR) 
indicated CTX and no 
HTX
OR
Data for CTX and/or HTX 
were missing or 
undocumented in the MR
CTX
ONLY 
Did you start 
taking HTX? 
Yes
No
Medical record (MR) 
indicated CTX and/or HTX 
OR
Data for CTX and/or HTX 
were missing or 
undocumented in the MR
BOTH CTX
AND HTX 
Did your doctor recommend chem
Yes
Figure 1. Selection criteria for CTX and HTX treatment history gfrom analyses, as were those who reported neurocognitive con-
cerns prior to treatment.
Results
Of 2,296 breast cancer survivors included in the study,
79% were married, 90% were white and non-Hispanic,
62% were employed for wages, 79% had invasive breast
cancer, and 54% were 45 years post-treatment whenber of CTX treatments 
re necessary?
Medical record (MR) indicated 
no CTX and no HTX 
OR
Data for CTX and/or HTX 
were missing undocumented 
in the MR
No
Did your doctor prescribe hormonal therapies 
(HTX), like tamoxifen (also called Nolvadex), 
Arimidex (anastrozole), Aromasin (exemestane), or 
Femara (letrozole) for your breast cancer? 
Did you start 
taking HTX? 
Yes
No
Yes
No
NO CTX / NO 
HTX GROUP
Medical record (MR) 
indicated HTX and no CTX
OR
Data for CTX and/or HTX 
were missing 
undocumented in the MR
HTX 
ONLY  
otherapy (CTX)?
No
roups.
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Table 2. Predictors of Reporting Neurocognitive Symptoms After Treatment Among Breast Cancer Survivors, Sister Study
Survivorship Survey, 2014
Neurocognitive concernsa
All breast cancer survivors Premenopausalb prior to treatment
Characteristics
Unadjusted OR,
OR (95% CI)
Fully adjusted OR,c
OR (95% CI)
Unadjusted OR,
OR (95% CI)
Fully adjusted OR,c
OR (95% CI)
Treatment history (ref: no CTX nor HTX)
CTX 6.48 (4.48, 9.35) 5.63 (3.52, 9.00) 6.21 (3.68, 10.48) 6.46 (3.19, 13.09)
HTX 1.48 (1.10, 1.99) 1.64 (1.15, 2.33) 1.78 (1.13, 2.81) 1.82 (1.05, 3.17)
CTX and HTX 8.00 (5.91, 10.82) 6.33 (4.21, 9.54) 7.35 (4.79, 11.28) 7.26 (3.92, 13.45)
Breast cancer type (ref: in situ)
Invasive 2.95 (2.38, 3.66) 1.12 (0.82, 1.53) 3.50 (2.55, 4.80) 1.00 (0.61, 1.63)
Race/ethnicity (ref: black, non-Hispanic)
White, non-Hispanic 1.21 (0.82, 1.78) 1.45 (0.89, 2.36) 1.20 (0.65, 2.24) 1.55 (0.76, 3.17)
Other race/ethnicity 1.52 (0.91, 2.55) 1.80 (0.94, 3.45) 1.19 (0.56, 2.55) 1.40 (0.58, 3.37)
Marital status (ref: single/never married)
Married/committed 0.91 (0.63, 1.31) 0.88 (0.56, 1.39) 1.14 (0.70, 1.86) 1.18 (0.66, 2.10)
Divorce/widowed 0.71 (0.47, 1.07) 0.92 (0.55, 1.53) 1.11 (0.61, 2.02) 1.33 (0.65, 2.73)
Years since dx (ref: o5 years)
Z5 years 2.18 (1.84, 2.58) 1.23 (0.97, 1.57) 1.49 (1.11, 2.00) 1.27 (0.89, 1.81)
Education (ref: rHS)
Some/associate/technical college 1.22 (0.92, 1.60) 1.14 (0.81, 1.60) 1.26 (0.82, 1.93) 1.46 (0.88, 2.42)
Four-year degree 1.44 (1.09, 1.89) 1.25 (0.89, 1.75) 1.32 (0.88, 1.98) 1.50 (0.93, 2.43)
Master’s and above 1.14 (0.87, 1.51) 1.04 (0.74, 1.46) 1.24 (0.81, 1.88) 1.39 (0.85, 2.28)
Age (years) at survey (ref: 34–44 years)
45–54 0.67 (0.39, 1.14) 0.80 (0.45, 1.45) 0.63 (0.36, 1.10) 0.77 (0.42, 1.41)
55–64 0.40 (0.23, 0.69) 0.58 (0.31, 1.09) 0.54 (0.30, 0.98) 0.74 (0.38, 1.43)
65–74 0.19 (0.11, 0.32) 0.32 (0.16, 0.63) —d —d
75–82 0.18 (0.10, 0.34) 0.31 (0.14, 0.67) —d —d
Menopausal status (ref: postmenopausal prior to tx)
Premenopausal throughout tx 1.76 (1.44, 2.16) 0.72 (0.51, 1.02) —e —e
Tx-induced menopause 2.94 (2.37, 3.65) 0.85 (0.60, 1.22) —e —e
Note: Boldface indicates statistical signiﬁcance (po0.05).
aRestricted to those who reported neurocognitive concerns during or after treatment but not prior to treatment.
bPremenopausal refers to women who were premenopausal prior to and remained premenopausal after treatment.
cAdjusted for all predictors including age at survey (10 year categories using dummy variable).
dWomen who reported being premenopausal and aged460 years at dx were excluded from the sample. After this exclusion, there were no women
who were aged465 years at the time of survey in the sample who reported being premenopausal prior to treatment.
eNot included in the model (no variability in the response).
CTX, chemotherapy; dx, diagnosis; HAT, hormonal adjuvant therapy for breast cancer; HS, high school; tx, treatment.
Buchanan et al / Am J Prev Med 2015;49(6S5):S498–S508 S503surveyed. More than half of respondents had a college
degree or higher and, because of inclusion criteria for
the Two Sister Study, many were aged 40–49 years atDecember 2015diagnosis (45%); aged 45–54 years at the time of survey
(40%); and half were premenopausal prior to
treatment.
Table 3. Predictors of Provider Discussion and/or Neurocognitive Treatment Among Survivors Reporting Neurocognitive
Concerns, Sister Study Survivorship Survey, 2014
Provider discussion about
neurocognitive symptoms,
Treatment for
neurocognitive symptoms,
Characteristics OR (95% CI) OR (95% CI)
Treatment history (ref: no CTX nor HTX)
CTX 1.69 (0.78, 3.66) 0.70 (0.28, 1.78)
HTX 1.09 (0.56, 2.15) 0.89 (0.41, 1.92)
CTX and HTX 1.63 (0.79, 3.36) 0.52 (0.22, 1.21)
BC type (ref: in situ)
Invasive 0.65 (0.37, 1.13) 0.73 (0.38, 1.40)
Race/ethnicity (ref: black, Non-Hispanic)
White, non-Hispanic 0.93 (0.46, 1.87) 1.09 (0.42, 2.81)
Other race/ethnicity 1.00 (0.41, 2.45) 2.02 (0.64, 6.34)
Marital status (ref: single/never married)
Married/committed 0.64 (0.36, 1.14) 0.83 (0.39, 1.78)
Divorce/widowed 0.70 (0.36, 1.35) 0.88 (0.37, 2.11)
Employment (ref: retired)
Employed for wages 0.77 (0.46, 1.28) 0.68 (0.34, 1.36)
Out of work 0.91 (0.50, 1.65) 1.02 (0.47, 2.22)
Other 1.10 (0.45, 2.69) 1.31 (0.42, 4.02)
Years since dx (ref: o5 years)
Z5 years 1.19 (0.85, 1.67) 1.03 (0.65, 1.64)
Education (ref: rHS)
Some/associate/technical college 1.38 (0.84, 2.25) 1.53 (0.74, 3.15)
Four-year degree 1.25 (0.77, 2.03) 1.50 (0.74, 3.06)
Master’s and above 1.77 (1.08, 2.93) 2.11 (1.02, 4.34)
Age (years) at survey (ref: 34–44 years)a
45–54 1.22 (0.65, 2.28) 1.11 (0.47, 2.61)
55–64 1.25 (0.63, 2.48) 0.94 (0.37, 2.44)
65–74 1.21 (0.51, 2.88) 0.94 (0.28, 3.10)
75–82 4.61 (1.50, 14.16) 1.92 (0.42, 8.75)
No. of daily living concerns (ref: 0–1)
2–3 1.63 (1.11, 2.39) 2.77 (1.46, 5.27)
4–5 2.26 (1.51, 3.39) 4.01 (2.09, 7.67)
6–8 4.93 (3.39, 7.17) 9.91 (5.58, 17.59)
First noticed neurocognitive symptoms (ref: 46 months after tx)b
During and o6 months after treatment 1.81 (1.28, 2.56) 1.00 (0.63, 1.60)
(continued on next page)
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Table 3. Predictors of Provider Discussion and/or Neurocognitive Treatment Among Survivors Reporting Neurocognitive
Concerns, Sister Study Survivorship Survey, 2014 (continued)
Provider discussion about
neurocognitive symptoms,
Treatment for
neurocognitive symptoms,
Characteristics OR (95% CI) OR (95% CI)
Menopausal status (ref: postmenopausal prior to tx)
Premenopausalc throughout tx 1.12 (0.72, 1.75) 1.24 (0.68, 2.27)
Tx-induced menopaused 1.07 (0.69, 1.64) 1.18 (0.65, 2.16)
Note: Boldface indicates statistical signiﬁcance (po0.05). All models adjusted for all predictors plus age (10 year categories, dummy variables).
aWomen who reported being premenopausal and aged460 years at dx were excluded from the sample.
bRestricted to those who reported neurocognitive concerns during or after treatment but not prior to treatment.
cPremenopausal refers to women who were premenopausal prior to and remained premenopausal after treatment.
dTx-induced menopause refers to women who were premenopausal prior to treatment and entered into menopause as a result of their treatment.
BCS, breast cancer survivors; CTX, chemotherapy; HTX, hormonal adjuvant therapy for breast cancer; tx, treatment.
Buchanan et al / Am J Prev Med 2015;49(6S5):S498–S508 S505Thirteen percent of all survivors were treated with
CTX alone, 36% with HTX alone, 37% with both, and
14% did not receive either treatment (Table 1). Demo-
graphic characteristics of survivors treated with CTX
alone or both CTX and HTX were similar (Table 1).
Those treated with CTX (with or without HTX) over-
whelmingly had invasive disease (99%), whereas 72% of
those treated with HTX alone had invasive disease.
Survivors not treated with either CTX or HTX had
predominantly in situ disease (70%; Table 1).
Sixty percent of survivors reported problems with
thinking, memory, and attention (Table 1). Of those,
60% ﬁrst noticed the problems within 6 months after
starting their primary breast cancer treatment and 76%
reported that their symptoms had either stayed the same
or gotten worse during the past 12 months (data not
shown). The majority of women who received CTX,
either alone or with HTX, reported cognitive problems
after treatment (74% and 78%, respectively). Forty-ﬁve
percent of women who received HTX alone also reported
post-treatment cognitive problems, as did 38% of those
who did not receive either treatment.
Most women with cognitive concerns, regardless of
treatment type, reported problems with concentration,
short-term memory, and recall memory. Thirty-seven
percent of women in all treatment groups reported
problems with organization. Difﬁculties with multitask-
ing were reported by 43% of women who received HTX
alone, 47% who received CTX alone or both treatments,
and 52% of those who received neither treatment. The
majority of women who received CTX, HTX, or both ﬁrst
noticed cognitive concerns o6 months after treatment
and reported that their symptoms had stayed the same or
worsened in the past 12 months.
In unadjusted models with all survivors, treatment
history, breast cancer type, years since diagnosis, educa-
tion, current age, and menopausal status at diagnosisDecember 2015were associated with reported neurocognitive concerns.
After simultaneous adjustment for the other variables in
Table 2, only treatment history and age at survey
remained signiﬁcant (p¼0.00). The odds for incident
neurocognitive concerns following treatment with CTX,
HTX, or both (compared with those with neither treat-
ment) remained elevated, though slightly attenuated.
Similarly, odds of neurocognitive concerns for those
who were aged Z65 years (vs 34–44 years) remained
below the null after adjustment, though slightly
attenuated.
Because unadjusted models showed that being
premenopausal prior to treatment was a predictor of
neurocognitive concerns, especially among those with
treatment-induced menopause (OR¼2.94, 95% CI¼2.37,
3.65), additional analyses of premenopausal women were
conducted (Table 2). Unadjusted models for survivors
who were premenopausal at treatment showed that
treatment history, breast cancer type, years since diag-
nosis, and (to a lesser extent) current age were predictors
of reported neurocognitive concerns. In the fully adjusted
model, for survivors who were premenopausal at treat-
ment, similar to results for all survivors, odds of report-
ing post-treatment neurocognitive problems remained
elevated among those who had a history of CTX; HTX; or
both treatments (compared with those with neither
treatment) with ORs of 6.46 (95% CI¼3.19, 13.09);
1.82 (95% CI¼1.05, 3.17); and 7.26 (95% CI¼3.92,
13.45), respectively.
Of those with cognitive concerns, only 37% reported
discussing their cognitive symptoms with a medical
provider. Of those, 30% reported receiving treatments
to address cognitive symptoms (data not shown). After
adjustment for all predictors, modeling showed that the
relative odds of having a provider discussion were
signiﬁcantly elevated for those who had a master’s degree
or above (compared with high school or lower); those
Buchanan et al / Am J Prev Med 2015;49(6S5):S498–S508S506who ﬁrst noticed their cognitive symptoms within 6
months of treatment (vs 46 months later); and those
who had two or more daily living concerns (compared
with none or one) (Table 3). Speciﬁcally, the odds of
having a provider discussion were increased twofold for
survivors reporting four to ﬁve daily living concerns and
increased almost ﬁvefold for survivors reporting six to
eight daily living concerns.
Among all respondents with cognitive concerns, 3%
received psychological testing, 4% received behavioral
therapy, 8% took prescription medications, and 8% used
alternative treatments to address cognitive difﬁculties
(data not shown). After adjustment, the relative odds of
receiving testing or treatment (behavioral and pharma-
cologic) for cognitive concerns were signiﬁcantly elevated
for those with a master’s degree or above (compared with
high school or lower) and those with two or more daily
living concerns (compared with those with none or one)
(Table 3). Speciﬁcally, the odds of reporting neuro-
cognitive treatment were four times higher for survivors
reporting four to ﬁve daily living concerns and almost ten
times higher for those reporting six to eight daily living
concerns.
Discussion
Treatment and demographic factors were associated with
reported cognitive concerns. The odds for reporting
cognitive concerns were ﬁve to six times higher for
survivors who received CTX or both CTX and HTX
(compared with neither treatment), consistent with the
literature showing increased cognitive impairment
among those treated with CTX (compared with no
CTX and individuals without cancer).20 The odds of
reported cognitive concerns were also greater for those
treated with HTX alone (compared with those with
neither treatment), which suggests that HTX has a role
in inducing cognitive impairment in breast cancer
survivors.21,22 Odds for reporting cognitive symptoms
following treatment were similarly elevated in analyses
restricted to survivors who were premenopausal prior to
being treated. Some studies have shown that postmeno-
pausal women report fewer cognitive concerns and may
even receive a cognitive beneﬁt from HTX.21
Among all survivors, those aged 455 years were less
likely to report incident cognitive problems. There is a
literature showing a positive association between cogni-
tive declines and increasing age.23 Thus, it is possible that
older survivors may attribute their cognitive concerns to
normal aging, rather than to their cancer experience.
Of the 60% of survivors with reported cognitive
concerns, only 37% reported having a related provider
discussion. Though there is a dearth of literatureregarding provider discussions about cognitive decline,
these ﬁndings are similar to estimates of psychosocial
provider discussions reported from the National Health
Interview Survey.9 This is not surprising, given that
provider discussions about mental health are not stand-
ard practice for many oncology providers.24 Low rates of
treatment receipt for cognitive symptoms are also con-
sistent with previously reported estimates of survivors’
engagement in supportive or treatment services to
address “psychosocial” concerns.9
In this study, the odds of having a provider discussion
about cognitive concerns were greater among those who
ﬁrst noticed cognitive symptoms within 6 months of
treatment, had a master’s degree or above, and reported
two or more daily living concerns. Survivors who ﬁrst
notice neurocognitive concerns within 6 months of treat-
ment may be more aware of cognitive decline and able to
associate declines with treatment when the problems ﬁrst
emerge during or soon after treatment. They may also have
more frequent contact with providers and subsequent
opportunities to initiate discussions.
Higher education levels and reporting two or more
daily living concerns were associated with increased odds
of having a provider discussion and also with receipt of
treatment for neurocognitive concerns. Higher education
has been associated with positive attitudes toward and
increased willingness to seek help for mental health
concerns and corresponding treatment.25–27 It is possible
that high education level among survivors might also be
associated with willingness to talk to providers about
neurocognitive concerns and seek out treatment. The
ﬁndings regarding education might also be indicative of
an increased level of situational awareness and metacog-
nition (e.g., knowledge about one’s cognition and factors
affecting cognition).28 Doctors might also perceive sur-
vivors with a high education level as having increased
ability to comprehend neurocognitive discussions.
Reporting two or more daily living concerns was also
predictive of having a provider discussion about neuro-
cognitive concerns. Survivors reporting problems with
six to eight activities of daily living were two to three
times more likely to talk to their provider and seek out or
accept treatment than those with only two to three
concerns of daily living. Increased disruption in daily
living activities may create a heightened level of urgency
and further motivate survivors to speak with providers
and accept treatment for cognitive symptoms in order to
improve their overall quality of life.
Overall, the present ﬁndings further validate other
population estimates showing low rates of provider
discussion and receipt of treatment for mental health
concerns, and illustrate gaps in achieving IOM-
recommended levels of psychosocial care.29www.ajpmonline.org
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Findings are based on data from a large sample of U.S.
adult female breast cancer survivors and contribute to the
existing literature by examining differences in reported
cognitive impairment as related to both CTX and HTX
treatment, as well as impairment related to menopausal
status at the time of treatment. Findings regarding the
use of neurocognitive treatments among breast cancer
survivors also add to the existing literature. Utilizing
the Sister and Two Sister Study cohorts provided a
unique opportunity to examine concerns in a cohort of
breast cancer survivors with a large number who were
aged o50 years at diagnosis. Additionally, few studies
have examined self-reported cognitive symptoms sepa-
rately from emotional/behavioral concerns when looking
at treatment and provider communication.
Study limitations include possible recall and reporting
biases and the absence of objective pre-and post-measures
of cognitive function. Although the sample of surveyed
breast cancer survivors was large, small numbers pre-
cluded interpretation of estimates for some questions.
Small numbers in some racial/ethnic categories was
another limitation. The sample was also a volunteer
cohort of women with sisters, which might limit general-
izability of study results. Lastly, given the large number of
statistical comparisons, some ﬁndings may be spurious.Conclusions
Research should continue to examine treatment-induced
neurocognitive concerns. Improved screening of neuro-
cognitive effects is needed for survivors who received
CTX and HTX. Conducting baseline and follow-up
cognitive assessments could help monitor progression
of cognitive concerns and determine if they improve on
their own or as a result of neurocognitive treatment.
Validation of self-reported data on neurocognitive con-
cerns with medical records and neuropsychological test-
ing results is also needed. In practice, better provider and
patient education is needed regarding screening for
cognitive late effects. Additionally, oncology nurses
may be helpful in assessing signs of cognitive decline
and educating patients about management strategies.30
Few neurocognitive treatments are evidence-based,
and further exploration is needed to determine their
efﬁcacy in alleviating cancer treatment–induced cogni-
tive impairment over time.31–34 Further investigation is
needed of optimal timing for neurocognitive interven-
tions so as not to cause or exacerbate cognitive deﬁcits.
Additionally, barriers and facilitators to provider
discussions about cognitive late effects could be explored.
Although survivors often undergo cancer treatments
despite the risk of side effects,35,36 some providers mayDecember 2015be reluctant to offer information about cognitive late
effects out of concern that patients could reject treatments
that may impact cognitive functioning. The essential
components of having an effective discussion about
cognitive decline should also be better deﬁned. Additional
practice standards of care could further incorporate
cognitive late effects information into care planning.
Lastly, the impact of billing and reimbursement policies
on provider discussion could be evaluated further.
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